Ensaios Clínicos

Fonte: https://euclinicaltrials.eu/

Estudos autorizados com recrutamento em curso

MASLD

A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes)

EUCT number: 2025-522674-36-00

Doenças hepatobiliares genéticas

A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F2 to F4 Fibrosis

EUCT number: 2022-501943-34-00

An Operationally Seamless Phase 1/2/3 Study Consisting of a Safety and Dose-finding Phase 1/2 and Randomized, Open-label, Active-controlled Phase 3 to Evaluate UX701 AAV Gene Therapy in Adults with Wilson Disease

EUCT number: 2022-502873-40-00

A Phase 3, Open-Label Extension Study to Evaluate the Log-Term Safety and Efficacy of Fazirsiran in Participants With Alpha-1 Antitrypsin Deficiency- Associated Liver Disease

EUCT number: 2023-503497-21-00

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1

EUCT number: 2023-504198-19-00

MRX-803 – Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients with Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)

EUCT number: 2024-516804-40-00

Doenças hepatobiliares autoimunes

A Phase III Randomised, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm Study to Evaluate the Efficacy and Safety of Elafibranor 80 mg on Long-Term Clinical Outcomes in Adult Participants With Primary Biliary Cholangitis (PBC)

EUCT number: 2023-505251-43-00

AFFIRM: A Randomized, Double.Blind, Placebo-Controlled, Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cirrhosis (PBC) and Compensated Cirrhosis

EUCT number:2024-516525-31-01

A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and safety of Elafibrabor in Adult Participants with Primary Sclerosing Cholangitis

EUCT number: 2026-525242-29-00

Doenças hepatobiliares oncológicas

A Phase III, Randomised, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR) altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308)

EUCT number: 2023-505660-11-00

DS7300-203 – A Phase 1b/2 pan-tumor, open-label study to evaluate the efficacy and safety of ifinatamab deruxtecan (I DXd) in subjects with recurrent or metastatic solid tumors

EUCT number: 2023-509632-26-00

Estudos em curso com recrutamento fechado

MASLD

NN9931-4553 – The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis

EUCT number: 2023-506962-30-00

337HNAS20011 – A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating efficacy and safety of lanifibranor followed by an active treatment extension in adult patient with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis

EUCT number: 2023-508248-23-00

Doenças hepatobiliares autoimunes 

A study to assess safety and efficacy of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis (PSC)

EUCT number:2024-511370-72-00

Doenças hepatobiliares oncológicas

A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE-158)

EUCT number: 2022-501253-37-00

An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard of-care therapy alone for advanced HER2 positive biliary tract cancer

EUCT number: 2023-508219-21-00

D910VC00001 – A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination with Tremelimumab ± Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compared to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-3)

EUCT number: 2023-508701-24-00